SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--ProSciento, Inc., a leading specialty clinical research organization (CRO) focused on non-alcoholic steatohepatitis (NASH), diabetes, obesity, and related metabolic diseases, announced today the closing of a growth financing from 1315 Capital, a healthcare investment firm that provides expansion and growth capital to commercial-stage healthcare services, medical technology and specialty therapeutics companies. SVB Leerink served as the exclusive financial advisor to ProSciento for this transaction.
The funds raised will support further expansion of the company’s CRO operations and the continued growth of ProSciento’s differentiated patient access solutions, including NASH PASS®, a novel and highly effective clinical research and patient registry platform.
“We are thrilled to partner with 1315 Capital to implement a number of strategic initiatives, including further expansion of our services, operations and key hires in the U.S. and key global markets. 1315 Capital has an impressive track record of working successfully with growth-stage companies in the therapeutics and healthcare services sector. We couldn’t be more pleased to work with the 1315 Capital team as we enter this stage of strategic expansion,” said Dr. Marcus Hompesch, Chief Executive Officer and Chairman of the Board at ProSciento.
“ProSciento has established an outstanding reputation as the leading provider of early stage clinical research services for metabolic diseases. With this differentiating expertise and an experienced leadership team, we believe the company is poised for significant growth as it continues to expand its CRO operations and leverages its proprietary NASH PASS program to improve clinical study design and enrollment for NAFLD and NASH drug development,” said Matthew Reber, Partner at 1315 Capital. “Our firm seeks to make a positive impact on patients and the entire healthcare system, and ProSciento is a key addition to the portfolio. We look forward to supporting ProSciento in its continued contributions to advance clinical research for metabolic diseases.”
About 1315 Capital, LLC
1315 Capital provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty therapeutics companies. 1315 Capital leverages experienced investors and proven operating teams to work alongside portfolio company management to rapidly grow platform companies into high value businesses that positively impact patients, physicians, and the broader healthcare system. For more information, visit www.1315capital.com.
About ProSciento, Inc.
ProSciento is a leading specialized clinical research organization (CRO) focused on NASH, diabetes, obesity, and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 300 clinical projects for diabetes, NASH, and obesity and supported the development of many approved metabolic drugs and devices on the market globally. For more information, please visit www.prosciento.com.